Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET – AUSTIN, TX and DURHAM, NC, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage...
November 03, 2021 17:19 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming November Investor Conferences

AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
October 28, 2021 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Changes to its Board of Directors

AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
October 01, 2021 09:56 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
September 01, 2021 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming September Conferences

AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
August 11, 2021 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252

– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for...
August 06, 2021 10:40 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in the BTIG Biotechnology Conference

AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
August 04, 2021 08:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021

AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
June 01, 2021 10:44 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer

AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
May 10, 2021 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights

– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – IND filings for...